

REMARKS

Claims 1-16 were pending and subjected to a restriction requirement. Claims 1-11 and 14 have been deleted, Claim 12, 13, 15, 16 have been amended, and claim 17 has been added. Applicant kindly request examination of all the pending claims

Restriction Requirement

Claims 1-16 were restricted according to three group. Applicant elects the invention of group III. Applicant has amended the claims accordingly so as to recite methods of treatment claims in the usual US format. Applicant further elects the species of the disease being insulin resistance. Claims 12, 13, and 15 read on this species.


Applicant further submit that the invention of claims 12, 15, 16 and 17 form a general inventive concept link by generic claim 12 wherein the mechanism of action is the inhibition of the enzyme glycosyl ceramide synthase. These inhibitors further exhibit additional inhibitory activity towards maltase and lactase which is relevant to all the listed diseases. Therefore Applicant requests that once patentability of the elected species is found, the examiner examine the remainder of the claims in the order listed in such claims.

Petition for Extension of Time

Applicant kindly requests a one month extension of time. The fee due for the extension is concomitantly submitted by electronic processing from the identified electronic portal address and charged to deposit account identified below..

If any additional fee is due, Applicants hereby authorize payment of such fee from Deposit Account 07-1074.

Respectfully submitted,



Isabelle A. S. Blundell, Ph.D.
Attorney for the Applicants
Reg. No. 43,321

Date January 21, 2009

Genzyme Corporation
153 Second Avenue
Waltham, MA 02451
Tel. No.: (781) 434-3524
Fax No.: (781) 895-4982
isabelle.blundell@genzyme.com